Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Bologna
About this trial
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years old or older
Capable of giving informed consent
Diagnosis of cancer scheduled for treatment according to treating physician's discretion
Life expectancy >1 year
Disqualifiers
Age <18 years old
Not able to give informed consent
Life expectancy <1 year
Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
Trial population
Confirmed diagnosis of cancer undergoing treatment
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
Combination productFollow-up visits at baseline, 3-months, and 1-year
Treatment groups
10,000 Participants
are divided into 2 treatment groupsGroup A: Breast cancer1 intervention
Group B: Female and Male0 interventions
Trial outcomes
Primary outcomes
1
All causes mortality
Occurrence of all cause death
Time frame
For approximately a median of 3 years2
Cardiovascular mortality
Occurrence of cardiovascular mortality
Time frame
For approximately a median of 3 years3
Cancer therapy-related cardiovascular toxicity
Occurrence of cancer therapy-related cardiovascular toxicity
Time frame
For approximately a median of 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Bologna
Lead sponsor
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Collaborator
Source ClinicalTrials.gov